These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28505124)

  • 1. Structure-Activity Relationships of Bioengineered Heparin/Heparan Sulfates Produced in Different Bioreactors.
    Kim HN; Whitelock JM; Lord MS
    Molecules; 2017 May; 22(5):. PubMed ID: 28505124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of bioengineered heparin/heparan sulfate production for therapeutic applications.
    Lord MS; Jung M; Whitelock JM
    Bioengineered; 2017 Sep; 8(5):661-664. PubMed ID: 28394734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet Factor 4 Binds to Vascular Proteoglycans and Controls Both Growth Factor Activities and Platelet Activation.
    Lord MS; Cheng B; Farrugia BL; McCarthy S; Whitelock JM
    J Biol Chem; 2017 Mar; 292(10):4054-4063. PubMed ID: 28115521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioengineered human heparin with anticoagulant activity.
    Lord MS; Cheng B; Tang F; Lyons JG; Rnjak-Kovacina J; Whitelock JM
    Metab Eng; 2016 Nov; 38():105-114. PubMed ID: 27445159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell glycosaminoglycans.
    Mulloy B; Lever R; Page CP
    Glycoconj J; 2017 Jun; 34(3):351-361. PubMed ID: 27900574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights.
    Coombe DR; Kett WC
    Cell Mol Life Sci; 2005 Feb; 62(4):410-24. PubMed ID: 15719168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation of syndecan 2 in the induction of stress fiber formation in cooperation with integrin alpha5beta1: structural characteristics of heparan sulfate chains with avidity to COOH-terminal heparin-binding domain of fibronectin.
    Kusano Y; Oguri K; Nagayasu Y; Munesue S; Ishihara M; Saiki I; Yonekura H; Yamamoto H; Okayama M
    Exp Cell Res; 2000 May; 256(2):434-44. PubMed ID: 10772816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serglycin-binding proteins in activated macrophages and platelets.
    Kolset SO; Mann DM; Uhlin-Hansen L; Winberg JO; Ruoslahti E
    J Leukoc Biol; 1996 Apr; 59(4):545-54. PubMed ID: 8613703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serglycin-independent release of active mast cell proteases in response to Toxoplasma gondii infection.
    Sawesi O; Spillmann D; Lundén A; Wernersson S; Åbrink M
    J Biol Chem; 2010 Dec; 285(49):38005-13. PubMed ID: 20864536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogenic activity of acidic fibroblast growth factor is enhanced by highly sulfated oligosaccharides derived from heparin and heparan sulfate.
    Gambarini AG; Miyamoto CA; Lima GA; Nader HB; Dietrich CP
    Mol Cell Biochem; 1993 Jul; 124(2):121-9. PubMed ID: 7694075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An enzyme-linked immunosorbent assay using biotinylated heparan sulfate to evaluate the interactions of heparin-like molecules and basic fibroblast growth factor.
    Foxall C; Holme KR; Liang W; Wei Z
    Anal Biochem; 1995 Nov; 231(2):366-73. PubMed ID: 8594987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of biosynthetic enzymes in heparin and heparan sulfate synthesis.
    Chappell EP; Liu J
    Bioorg Med Chem; 2013 Aug; 21(16):4786-92. PubMed ID: 23313092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c 3T3 cells: implications for potentiation of growth factor action by heparin.
    Brown KJ; Hendry IA; Parish CR
    J Cell Biochem; 1995 May; 58(1):6-14. PubMed ID: 7543903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation.
    Krufka A; Guimond S; Rapraeger AC
    Biochemistry; 1996 Aug; 35(34):11131-41. PubMed ID: 8780517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production methods for heparosan, a precursor of heparin and heparan sulfate.
    Chavaroche AA; van den Broek LA; Eggink G
    Carbohydr Polym; 2013 Mar; 93(1):38-47. PubMed ID: 23465899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches.
    Powell AK; Yates EA; Fernig DG; Turnbull JE
    Glycobiology; 2004 Apr; 14(4):17R-30R. PubMed ID: 14718374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoenzymatic synthesis of heparan sulfate and heparin.
    Liu J; Linhardt RJ
    Nat Prod Rep; 2014 Dec; 31(12):1676-85. PubMed ID: 25197032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains.
    Graham LD; Whitelock JM; Underwood PA
    Biochem Biophys Res Commun; 1999 Mar; 256(3):542-8. PubMed ID: 10080934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
    Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
    EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships.
    Rudd TR; Uniewicz KA; Ori A; Guimond SE; Skidmore MA; Gaudesi D; Xu R; Turnbull JE; Guerrini M; Torri G; Siligardi G; Wilkinson MC; Fernig DG; Yates EA
    Org Biomol Chem; 2010 Dec; 8(23):5390-7. PubMed ID: 20865198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.